Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

328 Press Releases
DateTitleCompany
14 Dec 12 U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis Pfizer Inc.,
Published by
Business Wire
09 Dec 12 ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment Pfizer Inc.,
Published by
Business Wire
05 Dec 12 Tanzania Expands Immunization Program To Include Pfizer’s Prevenar 13 For Prevention Of Pneumococcal Disease Pfizer Inc.,
Published by
Business Wire
05 Dec 12 Pfizer Presents Phase 2 Data Showing Investigational Therapy PD-0332991 Plus Letrozole Significantly Improved Progression Free Survival Compared With Letrozole Alone In Patients With ER Positive, HER2 Negative Advanced Breast Cancer Pfizer Inc.,
Published by
Business Wire
01 Dec 12 Pfizer Completes Sale of Nutrition Business to Nestlé Pfizer Inc.,
Published by
Business Wire
26 Nov 12 Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013 Pfizer Inc.,
Published by
Business Wire
21 Nov 12 ELIQUIS®(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation Pfizer Inc.,
Published by
Business Wire
19 Nov 12 Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release As Treatment For Patients With Fibromyalgia Pfizer Inc.,
Published by
Business Wire
16 Nov 12 Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures Pfizer Inc.,
Published by
Business Wire
07 Nov 12 U.S. Food and Drug Administration Approval of XELJANZ® (tofacitinib citrate) and Invitation to Media Briefing from Pfizer Pfizer Inc.,
Published by
Business Wire
07 Nov 12 U.S. Food and Drug Administration Approves Pfizer’s XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate Pfizer Inc.,
Published by
Business Wire
02 Nov 12 Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS® and Portola’s Universal Factor Xa Inhibitor Antidote PRT4445 Pfizer Inc.,
Published by
Business Wire
01 Nov 12 Pfizer Reports Third-Quarter 2012 Results Pfizer Inc.,
Published by
Business Wire
29 Oct 12 Pfizer Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to November 1, 2012 Due To Expected Severe Weather Conditions Pfizer Inc.,
Published by
Business Wire
26 Oct 12 Pfizer Declares A 22-Cent Fourth-Quarter 2012 Dividend Pfizer Inc.,
Published by
Business Wire
24 Oct 12 Pfizer’s XALKORI® Receives Conditional Marketing Authorization from the European Commission for the Treatment of Adults with Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU Pfizer Inc.,
Published by
Business Wire
22 Oct 12 Pfizer To Acquire NextWave Pharmaceuticals, Inc. Pfizer Inc.,
Published by
Business Wire
17 Oct 12 Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA® (axitinib) In Treatment-Naïve Patients With Advanced Renal Cell Carcinoma Pfizer Inc.,
Published by
Business Wire
16 Oct 12 New Study With CHANTIX®/CHAMPIX® (varenicline) Tablets Suggests Favorable Benefit-Risk Profile In Adult Smokers With Major Depressive Disorder Pfizer Inc.,
Published by
Business Wire
11 Oct 12 Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02: Pfizer Inc.,
Published by
Business Wire
10 Oct 12 New Report Reveals Programs That Promote Healthy Ageing Can Help Reduce Rising Health Costs1 Pfizer Inc.,
Published by
Business Wire
04 Oct 12 Pfizer Announces Top-Line Results Of Prevenar 13® Phase 3 Trial In Adults 18 To 49 Years Of Age Pfizer Inc.,
Published by
Business Wire
21 Sep 12 Pfizer Invites Public To View And Listen To Webcast Of October 30 Conference Call With Analysts Pfizer Inc.,
Published by
Business Wire
21 Sep 12 ELIQUIS® (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation Pfizer Inc.,
Published by
Business Wire
18 Sep 12 Pfizer Announces Data For Investigational Compound Tofacitinib In Rheumatoid Arthritis To Be Presented At The American College Of Rheumatology 2012 Annual Meeting Pfizer Inc.,
Published by
Business Wire
13 Sep 12 Pfizer And Hisun Announce Launch Of Hisun-Pfizer Pharmaceuticals Co., Ltd. Pfizer Inc.,
Published by
Business Wire
11 Sep 12 World Health Organization Grants Expansion To The Prequalification For Prevenar 13 To Include Adults 50 Years Of Age And Older Pfizer Inc.,
Published by
Business Wire
07 Sep 12 Pfizer Settles Patent Litigation with Mylan Covering Detrol LA® Pfizer Inc.,
Published by
Business Wire
05 Sep 12 U.S. Food and Drug Administration Approves BOSULIF® (bosutinib) for Patients with Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML) Pfizer Inc.,
Published by
Business Wire
04 Sep 12 Pfizer Receives EU Marketing Authorization for INLYTA® (Axitinib) Pfizer Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.